Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (NYSE:PFE) declared a $0.43 third-quarter 2026 cash dividend on its common stock. The dividend is payable September 1, 2026 to shareholders of record on July 24, 2026. This will be Pfizer’s 351st consecutive quarterly dividend, supporting its strategy to maintain and, over time, grow dividends.
Pfizer (NYSE:PFE) received U.S. FDA approval for IBRANCE (palbociclib) plus trastuzumab, with or without pertuzumab, and endocrine therapy as frontline maintenance treatment for adults with HR+, HER2+ locally advanced or metastatic breast cancer after induction.
Approval is supported by Phase 3 PATINA data showing a 24% reduction in risk of progression or death versus anti-HER2 and endocrine therapy alone, with safety consistent with the known IBRANCE profile.
Pfizer (NYSE:PFE) will host a webcast conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 4, 2026. The call will review Second Quarter 2026 results, detailed in Pfizer’s Performance Report issued that morning.
The live webcast, report, transcript and replay (available for at least 90 days) can be accessed via www.pfizer.com/investors. Phone dial-in is available for U.S./Canada and international participants.
Pfizer (NYSE:PFE) reported topline Phase 3 SigVie-002 results for sigvotatug vedotin in previously treated metastatic non-squamous NSCLC. The trial’s primary endpoint of overall survival was not met versus docetaxel in the overall population, though patients with only one prior therapy showed a stronger OS and PFS trend.
Safety was manageable and consistent with earlier studies. No clear IB6 expression–response relationship was seen. Pfizer is continuing development, including an ongoing Phase 3 trial of sigvotatug vedotin plus pembrolizumab in first-line advanced NSCLC and additional ADC programs across IB6 and PD-L1 targets.
Pfizer (NYSE:PFE) announced that Chief Financial Officer Dave Denton will leave the company on August 15, 2026 for a consumer goods role. Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, will become Interim CFO effective August 16, while Pfizer conducts an internal and external search.
Denton and Guegan will collaborate on a seamless transition. Guegan brings more than two decades at Pfizer and led key initiatives, including the 2024 integration of Seagen.
Pfizer (NYSE:PFE) received U.S. FDA approval to expand HYMPAVZI (marstacimab-hncq) for routine prophylaxis in adults and children ≥6 years with hemophilia A or B, with or without inhibitors.
HYMPAVZI becomes the first subcutaneous non-factor therapy for pediatric hemophilia B patients ages 6–11 in the U.S.
Pfizer (NYSE:PFE) reported Phase 2b results for berobenatide (PF’3944), a potential first-in-class monthly GLP-1 receptor agonist for obesity and related conditions.
Data showed up to 15.9% non-placebo-adjusted weight loss and a 2.2% HbA1c reduction, favorable tolerability, support for monthly dosing, and plans for 10 Phase 3 studies in 2026, including the pivotal VESPER-6 trial.
Pfizer (NYSE:PFE) will host a live webcast of a discussion with Chairman and CEO Albert Bourla at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 8:00 a.m. EDT.
The webcast, replay and transcript will be accessible via www.pfizer.com/investors, with replay and transcript available within 24 hours and remaining online for at least 90 days.
Pfizer (NYSE:PFE) reported updated Phase 3 BREAKWATER Cohort 3 data for BRAFTOVI plus cetuximab and FOLFIRI in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
The regimen nearly doubled median progression-free survival to 15.2 vs 8.3 months and showed a 44% reduction in risk of death. Based on BREAKWATER, the FDA granted full approval with an expanded indication in February 2026.
Pfizer (NYSE:PFE) reported Phase 3 TALAPRO-3 results showing TALZENNA plus XTANDI cut the risk of radiographic progression or death by 52% vs placebo plus XTANDI in HRR-mutated metastatic castration-sensitive prostate cancer (HR=0.48; p<0.0001).
Estimated three-year rPFS was 77% vs 56%, with median rPFS not reached vs 46 months. Benefits appeared consistent across BRCA and non-BRCA subgroups. Overall survival trends favored the combination (HR=0.77; p=0.09). Safety aligned with known profiles; anemia (grade ≥3) occurred in 51% vs 3% of patients.